Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Sees Increasing Appetite For Innovative Products – PharmAsia Summit

This article was originally published in PharmAsia News

Executive Summary

China's life sciences industry is at a crossroads, and new commercial models are needed to drive future growth, but a disconnect between corporate strategies may derail execution.

You may also be interested in...



Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model

In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding

China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March

Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.

Topics

Related Companies

UsernamePublicRestriction

Register

SC082253

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel